Document is current
Any future updates will be listed below
-
Authors
Cattaneo, Marco
Bonanomi, Marcella
Chirizzi, Cristina
Malacarne, Claudia
Giagnorio, Eleonora
Farinazzo, Giorgia
Bonanno, Silvia
Porro, Danilo
Lauria, Giuseppe
Metrangolo, Pierangelo
Bombelli, Francesca Baldelli
Gaglio, Daniela
Marcuzzo, Stefania
-
Funding
Funding for this research was provided by:
Fondazione Regionale per la Ricerca Biomedica POR FESR (1157625)
Italian Ministry of University and Research (MIUR)—ELIXIR-IT through the empowering project ELIXIRNextGenIT (IR0000010)
Italian Ministry of Health
CALabria HUB per Ricerca Innovativa ed Avanzata (T4-AN-09)
- License Information
-
More Information
Article History
Received: 9 June 2025
Accepted: 7 October 2025
First Online: 13 November 2025
Declarations
:
: The authors declare no competing interests.
: All animal experiments were carried out in accordance with the EU Directive 2010/63 and with the Italian law (D.L. 26/2014) on the protection of animals used for scientific purposes. Transgenic G93A-SOD1 (B6SJL-Tg (SOD1*G93A)1Gur/J) [MGI: 2183719] and control B6.SJL mice were purchased from Charles River Laboratories, Inc. (Wilmington, MA, USA), maintained and bred at the animal house of the Fondazione IRCCS Istituto Neurologico Carlo Besta in compliance with institutional guidelines. The project was approved by the Ethics Committee of the Institute and the Italian Ministry of Health (ref. 78/2022-PR, “Malattie del motoneurone: studio di microRNA in modelli sperimentali per l’ottimizzazione della diagnosi e l’identificazione di potenziali trattamenti terapeutici”).
: Not applicable.
